- Home
- MCRB vs ADCT Comparison
MCRB vs ADCT Comparison
Compare MCRB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- ADCT
- Stock Information
- Founded
- MCRB 2010
- ADCT 2011
- Country
- MCRB United States
- ADCT Switzerland
- Employees
- MCRB N/A
- ADCT N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- MCRB Health Care
- ADCT Health Care
- Exchange
- MCRB Nasdaq
- ADCT Nasdaq
- Market Cap
- MCRB 141.9M
- ADCT 143.1M
- IPO Year
- MCRB 2015
- ADCT 2020
- Fundamental
- Price
- MCRB $0.80
- ADCT $1.63
- Analyst Decision
- MCRB Buy
- ADCT Strong Buy
- Analyst Count
- MCRB 4
- ADCT 5
- Target Price
- MCRB $5.63
- ADCT $8.00
- AVG Volume (30 Days)
- MCRB 844.5K
- ADCT 480.5K
- Earning Date
- MCRB 03-04-2025
- ADCT 03-12-2025
- Dividend Yield
- MCRB N/A
- ADCT N/A
- EPS Growth
- MCRB N/A
- ADCT N/A
- EPS
- MCRB N/A
- ADCT N/A
- Revenue
- MCRB $126,325,000.00
- ADCT $70,717,000.00
- Revenue This Year
- MCRB N/A
- ADCT $6.81
- Revenue Next Year
- MCRB N/A
- ADCT $11.23
- P/E Ratio
- MCRB N/A
- ADCT N/A
- Revenue Growth
- MCRB 12856.41
- ADCT N/A
- 52 Week Low
- MCRB $0.54
- ADCT $1.39
- 52 Week High
- MCRB $1.53
- ADCT $5.38
- Technical
- Relative Strength Index (RSI)
- MCRB 46.38
- ADCT 46.49
- Support Level
- MCRB $0.81
- ADCT $1.55
- Resistance Level
- MCRB $0.84
- ADCT $1.73
- Average True Range (ATR)
- MCRB 0.04
- ADCT 0.12
- MACD
- MCRB 0.00
- ADCT 0.03
- Stochastic Oscillator
- MCRB 45.58
- ADCT 63.16
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.